Protalix $PLX blew past Q3 estimates: revenue of $21.9M vs about $12.4M expected, and EPS of $0.05 vs a projected $0.02 loss. The driver was product sales, not

Protalix $PLX blew past Q3 estimates: revenue of $21.9M vs about $12.4M expected, and EPS of $0.05 vs a projected $0.02 loss. The driver was product sales, not milestones: higher Elfabrio sales to partner Chiesi, with faster patient uptake in Europe after an every-four-weeks dosing approval. Protal…